Trial reportClinical and translational science2026
Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies.
Trial report in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ibuprofen is the most commonly used NSAID; however, its short biological half-life, reflected in the short duration of pain relief, limits the comfortableness of its usage. This study evaluated the pharmacokinetic properties of a newly developed biphasic ibuprofen 400 mg immediate-release/sustained-release (IR/SR) modified-release tablets (test formulation), which was developed with an aim to overcome a need for frequent dosing. Both single-dose and multiple-dose, open-label, randomized, crossover studies compared the bioavailability of the test formulation with two Nurofen 200 mg, immediate-release coated tablets (reference formulation) administered within 4 h intervals. In addition, the effect of food on the test formulation performance was evaluated in a single-dose, open-label, randomized, crossover, bioavailability study. Based on the 95% confidence intervals of the geometric mean ratios, the new test formulation exhibited equivalent (80.00-125.00%) total (AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.